Cohance Lifesciences Limited (BOM:543064)

Market Cap	337.23B
Revenue (ttm)	12.59B
Net Income (ttm)	2.41B
Shares Out	n/a
EPS (ttm)	9.40
PE Ratio	139.71
Forward PE	53.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,841
Average Volume	85,856
Open	863.15
Previous Close	860.95
Day's Range	863.15 - 884.35
52-Week Range	856.90 - 1,359.00
Beta	n/a
RSI	42.62
Earnings Date	Nov 12, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.